Abstract: A stent arrangement which has at least a first ring (3) and zig zag struts (5) extending axially from the periphery of the ring. There can be first and second rings (3, 4) axially spaced apart and defining substantially parallel planes and a plurality of zig zag portions (5) between the first and second ring portions around the periphery thereof. The stent can be formed from a single wire or laser cut from a cannula and can be covered or uncovered.

Abstract: A stent graft (1) including a tubular wall (3) with at least one fenestration (40) including a peripheral (37) reinforcement around at least part of the fenestration. There can also be a tubular extension (15). The side arm includes a stent (19) and a cover (17) and extends from and is in fluid communication with the fenestration and the stent graft. The stent may be a self expanding stent. The ring and/or tubular extension provides better support and sealing for an extension arm. The fenestration (40) can be circular or if towards the ends of the stent graft may be in the form of a U-shape (50) with an open end.

Abstract: An endovascular stent graft assembly (10) for use with abdominal aorta aneurysms (70) and having a main stent graft body (12) and a separate attachment graft tube (14) that extends proximally therefrom having the proximal attachment stent (50) thereon for infrarenal attachment of the assembly (10) to the aorta (74). A distal end portion (44) of the attachment graft tube (14) underlies the proximal end portion (30) of the main stent graft body (12) and presses outwardly there against forming a a friction fit, at an overlapping region (64). The main stent graft body (12) has an ipsilateral leg (22) and a contralateral stump (24) at the bifurcation (26); and prior to deployment of the attachment graft tube (14), the main stent graft body is pulled against the vessel bifurcation (72). After deployment of the attachment graft tube (14), the contralateral leg (16) is deployed at the contralateral stump to complete the stent graft assembly (10).

Abstract: A wireless communications device (102) includes a flip assembly 106 that includes a speaker (120) and that has a GPS antenna (104) mounted about a far edge. The flip assembly (106) further has a GPS RF amplifier (314) mounted adjacent to the GPS antenna (104) for amplifying signals received by the GPS antenna (104) and providing those amplified signals to a GPS RF stripline (312). The GPS RF stripline (312) includes a flexible RF stripline (404) to accommodate rotationally opening and closing of the flip assembly (106). Positioning of the GPS antenna (104) about the far edge of the flip assembly (106) removes the GPS antenna from a main housing assembly (108) of the wireless communications device (102) and provides for better GPS signal reception performance.

Abstract: The invention provides the compounds of formula (I) and pharmaceutically acceptable derivatives thereof, in which: R1 and R2 are independently selected from H, C1-6 alkyl, C2-6alkenyl, C3-6alkynyl, C3-10cycloalkylC0-6alkyl or C4-12bridged cycloalkane; and R3 is C1-6alkyl or NH2. Compounds of formula (I) are potent and selective inhibitors of COX-2 and are of use in the treatment of pain, fever, inflammation and a variety of conditions and diseases.

Abstract: Therapeutically active thiazole derivatives of formula (I) wherein R1, R2, X and X′ are as defined in the specification, processes for the preparation thereof, the use thereof in therapy, particularly in the treatment or prophylaxis of disorders characterized by overexpression of transforming growth factor &bgr;(TAG-&bgr;), and pharmaceutical compositions for use in such therapy.

Abstract: Therapeutically active pyrazole derivatives of formula (I) wherein R1-R3 are as defined in the specification, processes for the preparation thereof, the use thereof in therapy, particularly in the treatment or prophylaxis of disorders characterised by overexpression of transforming growth factor (TGF-), and pharmaceutical compositions for use in such therapy.

Abstract: An endovascular stent graft assembly (10) for use with abdominal aorta aneurysms (70) and having a main stent graft body (12) and a separate attachment graft tube (14) that extends proximally therefrom having the proximal attachment stent (50) thereon for infrarenal attachment of the assembly (10) to the aorta (74). A distal end portion (44) of the attachment graft tube (14) underlies the proximal end portion (30) of the main stent graft body (12) and presses outwardly there against forming a a friction fit, at an overlapping region (64). The main stent graft body (12) has an ipsilateral leg (22) and a contralateral stump (24) at the bifurcation (26); and prior to deployment of the attachment graft tube (14), the main stent graft body is pulled against the vessel bifurcation (72). After deployment of the attachment graft tube (14), the contralateral leg (16) is deployed at the contralateral stump to complete the stent graft assembly (10).

Abstract: The present invention relates to a novel process for the preparation of R-(+)-6-carboxamido-3-N-methylamino-1,2,3,4-tetrahydrocarbazole.

Abstract: An endovascular stent graft assembly (10) for use with abdominal aorta aneurysms (70) and having a main stent graft body (12) and a separate attachment graft tube (14) that extends proximally therefrom having the proximal attachment stent (50) thereon for infrarenal attachment of the assembly (10) to the aorta (74). A distal end portion (44) of the attachment graft tube (14) underlies the proximal end portion (30) of the main stent graft body (12) and presses outwardly there against forming a a friction fit, at an overlapping region (64). The main stent graft body (12) has an ipsilateral leg (22) and a contralateral stump (24) at the bifurcation (26); and prior to deployment of the attachment graft tube (14), the main stent graft body is pulled against the vessel bifurcation (72). After deployment of the attachment graft tube (14), the contralateral leg (16) is deployed at the contralateral stump to complete the stent graft assembly (10).

Abstract: The invention provides compounds of the general formula (I) ##STR1## or a physiologically acceptable salt or solvate thereof, wherein Q represents a 1- or 2-naphthalenyl group.The compounds have a stimulant action at .beta..sub.2 -adrenoreceptors and may be used in the treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis.

Abstract: The invention provides a method of treatment of diseases associated with reversible airways obstruction such as asthma and chronic bronchitis, utilizing the compounds of the formula ##STR1## or a physiological acceptable salt or solvate thereof, wherein Q represents a 1- or 2- naphthalenyl group.

Abstract: The invention provides compounds of the general formula (I) ##STR1## and physiologically acceptable salts and solvates thereof, wherein AR represents the group ##STR2## where Q.sup.1 represents a straight or branched C.sub.1-3 alkylene group, ##STR3## where Q.sup.2 represents a group R.sup.3 CO--, R.sup.3 NHCO--, R.sup.3 R.sup.4 NSO.sub.2 --, or R.sup.5 SO.sub.2 --, where R.sup.3 and R.sup.4 each represent a hydrogen atom or a C.sub.1-3 alkyl group, and R.sup.5 represents a C.sub.1-3 alkyl group, ##STR4## R represents a hydrogen atom or a C.sub.1-3 alkyl group; R.sup.1 and R.sup.

Abstract: The invention provides compounds of the general formula (I) ##STR1## and physiologically acceptable salts and solvates thereof, wherein Ar represents the group ##STR2## where Q.sup.1 represents a straight or branched C.sub.1-3 alkylene group, ##STR3## where Q.sup.2 represents a group R.sup.3 CO--, R.sup.3 NHCO--, R.sup.3 R.sup.4 NSO.sub.2 -- or R.sup.5 SO.sub.2 --, where R.sup.3 and R.sup.4 each represent a hydrogen atom or a C.sub.1-3 alkyl group, and R.sup.5 represents a C.sub.1-3 alkyl group, ##STR4## R represents a hydrogen atom or a C.sub.1-3 alkyl group; R.sup.1 and R.sup.

Abstract: This invention relates to compounds of the general formula (I) and physiologically acceptable salts and solvates thereof whereinAr represents ##STR1## where R.sup.3 is a bond or a straight or branched C.sub.1-2 alkylene group,R.sup.4 is a hydroxy group or a group R.sup.5 NH-- whereR.sup.5 represents a group CH.sub.3 SO.sub.2 --, HCO-- or NH.sub.2 CO--, ##STR2## where R.sup.6 is a chlorine atom or the group F.sub.3 C--, ##STR3## k represents an integer from 1 to 8, m represents zero or an integer from 2 to 7 andn represents an integer from 2 to 7 with the proviso that the sum total of k, m and n is 4 to 12;R.sup.1 and R.sup.2 each represents a hydrogen atom or a methyl or ethyl group with the proviso that the sum total of carbon atoms in R.sup.1 and R.sup.2 is not more than 2;R.sup.30 represents hydrogen or C.sub.

Abstract: A saddle rack has a plurality of flat planar pieces which are stackable one on the other for storage. The pieces can temporarily be connected together into a self supporting saddle rack. Included among the pieces are first and second vertical end elements, a lower horizontal cross member and a plurality of upper horizontal cross members. The lower horizontal cross member has ends with each of the ends temporarily connectable to one of the end elements. Each of the upper horizontal have ends with each of the ends temporarily connectable to the top of one of the end elements.

Abstract: Compounds of the formula (I) ##STR1## (in which X represents HS-- or a group R.sub.1 R.sub.2 N-- wherein R.sub.1 and R.sub.2 which may be the same or different represent hydrogen or a straight or branched chain alkyl group containing from 1 to 4 carbon atoms or a benzyl group and R.sub.3 represents a C.sub.3-7 alkyl group or a C.sub.3-7 cycloalkyl group) are prepared by reacting an .alpha.-ketoester of the formula (II) ##STR2## (in which Alk represents an alkyl group) or a precursor thereof with a compound of the formula (III) ##STR3## The precursor of the compound of formula (II) may be a mixture of isomeric enol esters ##STR4## The compounds of formula (I) may be converted into compounds of formula VIII ##STR5## in which R.sub.1 and R.sub.2 which may be the same or different represent hydrogen or a straight or branched chain alkyl group containing from 1 to 4 carbon atoms, and R.sub.3 is as defined above.

Abstract: There are provided compounds of the general formula (I): ##STR1## and physiologically acceptable salts thereof in which Z represents a group ##STR2## wherein R.sub.2 represents a hydrogen atom or a straight or branched chain alkyl radical, or Z can additionally represent a group ##STR3## and R.sub.1, R.sub.3 and R.sub.4, which may be the same or different, each represent a hydrogen atom, a cycloalkyl group, an aryl group which may optionally be substituted by one or more hydroxy, alkoxy, or halogen radicals, or a straight or branched alkyl or alkenyl group, which alkyl or alkenyl group may be substituted with an aryl group, which aryl group may optionally be substituted by one or more hydroxy, alkoxy or halogen radicals. The compounds possess spasmolytic and cAMP phosphodiesterase inhibitory activity.

Abstract: An anaerobic adhesive comprising as a bond forming system a polymerizable aromatic-based acrylate monomer and a compatible liquid butadiene acrylonitrile copolymer, together with a latent initiator for the polymerization, said aromatic based acrylate monomer having the general formula ##STR1## where: Ar is a divalent aromatic residue;R.sub.1 and R.sub.2 represent hydrogen, alkyl, aryl, or hydroxyalkyl groups, or halogen; andR.sub.3 and R.sub.4 represent ##STR2## where m is an integer of from 1 to 20 and R.sub.5, R.sub.6, and R.sub.7 represent hydrogen, alkyl, or alkoxy groups, or halogen, the same or different.

Abstract: A composition for coating a metal-working tool to increase tool life, comprising graphite, molybdenum disulphide or other solid lubricant in an aqueous binder solution comprising a phosphate of aluminium, magnesium, zinc, calcium or other metal and preferably a chromate or dichromate as well.